Drug intelligence / Profile preview

MB-AD-101

Development stage: Preclinical
Lead developer: Mercury Bio
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

MB-AD-101 is an experimental intracellular immunotherapeutic nanobody being developed by Mercury Bio (Mercury Holdings) for the treatment of Alzheimer's disease. The drug is designed to utilize a proprietary delivery platform that enables it to cross the blood-brain barrier (BBB) and enter neurons. Once inside the cell, the nanobody is intended to bind to and modulate intracellular pathogenic proteins that are implicated in the progression of Alzheimer's disease. As of early 2024, the program is in the early preclinical stage of development.

Beyond the preview

Go deeper on MB-AD-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-AD-101.

Explore the full profile